chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Poor quality product administered, Product temperature excursion issue
Clinical narrative: patient received dose of Moderna vaccine post excursion; patient received dose of Moderna vaccine post excursion; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion).    Concomitant product use was not provided by the reporter.  Treatment information was not provided.  This case contains information for the 19th of 19 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-706941, US-MODERNATX, INC.-MOD-2023-706966 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-706941:Patient 1 of 19 US-MODERNATX, INC.-MOD-2023-706966:Patient 19 of 19
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Poor quality product administered, Product temperature excursion issue
Clinical narrative: patient received dose of Moderna vaccine post excursion; patient received dose of Moderna vaccine post excursion; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion), POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion), POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion), POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion) and POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion).    Concomitant medication was not reported. Treatment drug was not reported. This case contains information for the 18th of 19 patients reported by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-706941 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-706941
Age: 4.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Dose administered after 30-day Use By Date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) in a 4-year-old female child exposed to mRNA-1273 (Spikevax) (batch no. AS1412B) , while the mother received the product for COVID-19 prophylaxis.    MEDICAL HISTORY (Parent): Concurrent medical conditions included Maternal exposure during breast feeding.    MEDICAL HISTORY (Patient): No allergy, concomitant diseases and risk factor was reported.     On 10-Jan-2023, the mother received second dose of mRNA-1273 (Spikevax) (Transmammary) .25 milliliter. Last menstrual period and estimated date of delivery were not provided. On 10-Jan-2023, the child was diagnosed with EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date). On an unknown date, the child was diagnosed with NO ADVERSE EVENT (No adverse event). The Child was exposed to mRNA-1273 (Spikevax) during pregnancy. The delivery occurred  on 20-Feb-2018, which was reported as Unknown. For neonate 1, The outcome was reported as Delivered NOS. At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date).    No concomitant and treatment medications were reported.  Patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.
Age: 40.0
Sex: M
Vaccine: UNK
Symptoms: Arthralgia, Chills, Fatigue, Headache, Mobility decreased
Clinical narrative: Pain in shoulder, unable to lift above the waist.  Fever, chills, headache, body aches, fatigue, sleepiness  All occurring 24 hours after vaccination. No treatment.   Most symptoms passed by day 4
Age: 40.0
Sex: M
Vaccine: UNK
Symptoms: Pain, Pyrexia, Somnolence
Clinical narrative: Pain in shoulder, unable to lift above the waist.  Fever, chills, headache, body aches, fatigue, sleepiness  All occurring 24 hours after vaccination. No treatment.   Most symptoms passed by day 4
Age: 2.0
Sex: M
Vaccine: HEPA
Symptoms: Erythema, Skin warm
Clinical narrative: Red, warm area the size of a palm.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Bronchitis, COVID-19, Herpes zoster, Muscle spasms, SARS-CoV-2 test positive
Clinical narrative: I had muscle spasms in my right arm after receiving the vaccine. I tested positive for COVID-19 in May 2022. In August 2022, I developed Shingles and I have had multiple outbreaks since receiving the vaccine. Also, I developed bronchitis.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding
Clinical narrative: Heavy period, more painful period, period lasting 2 days longer than normal
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Patient vaccinated against then tested positive for COVID-19
Age: 61.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Chest discomfort, Cough, Fatigue, Influenza virus test
Clinical narrative: On  15Sunday2023 I started to feel very tired and my chest started to feel very tight so I took some Pepcid it did no t really help, I got finished with dinner got home and got in bed and felt like crap then I began to get cramps in my legs then I got congestion in my head and a cough which doesn't normally happen, my daughter took me to the Doctor and I was tested for influenza and  COVID-19 and tested positive. I stayed at a hotel for six days. On the seventh day when I flew home I felt worse.  I was still sick for four more days and I called the Doctor, he thought I had a secondary and prescribed Cefuroxime and a cough medicine.
Age: 61.0
Sex: F
Vaccine: COVID19-2
Symptoms: Malaise, Muscle spasms, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: On  15Sunday2023 I started to feel very tired and my chest started to feel very tight so I took some Pepcid it did no t really help, I got finished with dinner got home and got in bed and felt like crap then I began to get cramps in my legs then I got congestion in my head and a cough which doesn't normally happen, my daughter took me to the Doctor and I was tested for influenza and  COVID-19 and tested positive. I stayed at a hotel for six days. On the seventh day when I flew home I felt worse.  I was still sick for four more days and I called the Doctor, he thought I had a secondary and prescribed Cefuroxime and a cough medicine.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Patient vaccinated against then tested positive for COVID-19
Age: 82.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Patient vaccinated against then tested positive for COVID-19
Age: 36.0
Sex: F
Vaccine: COVID19-2, UNK
Symptoms: Cough, Exposure to SARS-CoV-2, Fatigue, Feeling abnormal, Headache
Clinical narrative: Husband tested positive for COVID-19 and so he brought it home to me. I started having symptoms of headache, congestion, brain fog, and major fatigue. I have developed a cough as well and the headache and congestion have gotten worse. I ended up going to urgent care as well for a test. I have had body aches as well and then the fatigue has just been horrible; I have never been this tired from an illness before.
Age: 36.0
Sex: F
Vaccine: COVID19-2, UNK
Symptoms: Pain, Respiratory tract congestion, SARS-CoV-2 test
Clinical narrative: Husband tested positive for COVID-19 and so he brought it home to me. I started having symptoms of headache, congestion, brain fog, and major fatigue. I have developed a cough as well and the headache and congestion have gotten worse. I ended up going to urgent care as well for a test. I have had body aches as well and then the fatigue has just been horrible; I have never been this tired from an illness before.
Age: 9.0
Sex: F
Vaccine: COVID19-2
Symptoms: Blood culture negative, COVID-19, Cough, Febrile neutropenia, Laboratory test
Clinical narrative: Name:  Date of Birth: MRN:    Primary Care Physician at Discharge: MD Hematologist/Oncologist:  MD Admission Date: 1/27/2023 Discharge Date: 01/30/2023   PRESENTING PROBLEM: Febrile neutropenia (HCC)  COVID   HOSPITAL COURSE: Patient is a 9 y.o. female with B-cell ALL in remission on maintenance therapy and history of PRES with seizures who was admitted on 1/27/2023 for febrile neutropenia.   She was febrile to 99F at home with cough and congestion. She presented to the ED where she was found to have a Tmax of 39.2. Fastbreak protocol was initiated. She was started on Cefepime q8h and both peripheral and central cultures were drawn. Cultures remained no growth during admission. Respiratory film array was positive for COVID-19 infection. Labs were significant for WBC of 650 and ANC of 140. She was admitted to the pediatric hematology/oncology service for further management. She was continued on cefepime and her home epilepsy medications.  Patient remained afebrile without the use of antipyretics while admitted. Per discussions with ID without a formal consult, a three day course of Remdesivir was started. A full five day course was unnecessary as she was not hypoxic throughout admission.   While inpatient, her home chemo regimen of 6-mercaptopurine and methotrexate was held due to low ANC levels. She was given GCSF x3. ANC on 1/30 was 200, and she was given her last dose of GCSF before discharge with plans to repeat CBC on 2/2.    Patient was discharged home on 1/30 with plans to follow-up in the outpatient clinic on 2/17 or sooner if needed. She was instructed to call with any new fever.   NUDT15 enzyme test was sent out to clinic Lab while patient was admitted. This will require follow-up as an outpatient.
Age: 9.0
Sex: F
Vaccine: COVID19-2
Symptoms: Neutrophil count decreased, Respiratory tract congestion, SARS-CoV-2 test positive, White blood cell count increased
Clinical narrative: Name:  Date of Birth: MRN:    Primary Care Physician at Discharge: MD Hematologist/Oncologist:  MD Admission Date: 1/27/2023 Discharge Date: 01/30/2023   PRESENTING PROBLEM: Febrile neutropenia (HCC)  COVID   HOSPITAL COURSE: Patient is a 9 y.o. female with B-cell ALL in remission on maintenance therapy and history of PRES with seizures who was admitted on 1/27/2023 for febrile neutropenia.   She was febrile to 99F at home with cough and congestion. She presented to the ED where she was found to have a Tmax of 39.2. Fastbreak protocol was initiated. She was started on Cefepime q8h and both peripheral and central cultures were drawn. Cultures remained no growth during admission. Respiratory film array was positive for COVID-19 infection. Labs were significant for WBC of 650 and ANC of 140. She was admitted to the pediatric hematology/oncology service for further management. She was continued on cefepime and her home epilepsy medications.  Patient remained afebrile without the use of antipyretics while admitted. Per discussions with ID without a formal consult, a three day course of Remdesivir was started. A full five day course was unnecessary as she was not hypoxic throughout admission.   While inpatient, her home chemo regimen of 6-mercaptopurine and methotrexate was held due to low ANC levels. She was given GCSF x3. ANC on 1/30 was 200, and she was given her last dose of GCSF before discharge with plans to repeat CBC on 2/2.    Patient was discharged home on 1/30 with plans to follow-up in the outpatient clinic on 2/17 or sooner if needed. She was instructed to call with any new fever.   NUDT15 enzyme test was sent out to clinic Lab while patient was admitted. This will require follow-up as an outpatient.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Cognitive disorder, Diarrhoea, Disorientation
Clinical narrative: The day before my daughter had tested positive so I was just anticipating getting COVID-19 myself since we live together. The next day, I started with a fever, and I also had a headache the next day only had a low-grade fever that lasted for three days. I tested positive for COVID-19. I messaged the doctor and the next day she called me and let me know she was calling in Paxlovid. I started taking the medication 2 days later and did a few telehealth appointments. Then I started to feel disorientated let cognitive I had a hard time recognizing some things. I was extremely fatigue and weak. About a week into these symptoms, I developed diarrhea that lasted a week. It was horrible and like water going straight through me.  I was going through so much from the symptoms and the treatment I don't know if I felt better, I was just going through so much for weeks at a time. It was 4-5 weeks to recover..
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure to SARS-CoV-2, Fatigue, Headache, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: The day before my daughter had tested positive so I was just anticipating getting COVID-19 myself since we live together. The next day, I started with a fever, and I also had a headache the next day only had a low-grade fever that lasted for three days. I tested positive for COVID-19. I messaged the doctor and the next day she called me and let me know she was calling in Paxlovid. I started taking the medication 2 days later and did a few telehealth appointments. Then I started to feel disorientated let cognitive I had a hard time recognizing some things. I was extremely fatigue and weak. About a week into these symptoms, I developed diarrhea that lasted a week. It was horrible and like water going straight through me.  I was going through so much from the symptoms and the treatment I don't know if I felt better, I was just going through so much for weeks at a time. It was 4-5 weeks to recover..
Age: 54.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Condition aggravated, Cough, Dyspnoea, Interstitial lung disease, Oxygen saturation decreased
Clinical narrative: Shortness of Breath, Low Oxygen Saturation, Coughing Interstitial Lung Disease Flare
Age: 57.0
Sex: F
Vaccine: COVID19-2
Symptoms: Peripheral swelling
Clinical narrative: Arms swelling more than usual.
Age: 87.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Dyspnoea, Fatigue, SARS-CoV-2 test positive
Clinical narrative: 01/03/23 presents to ED for "breathing problem, fatigue". PMHx of "A. fib, MI with stents, pacemaker placement, CHF, and adrenal insufficiency"
Age: 40.0
Sex: F
Vaccine: COVID19-2, FLUA4
Symptoms: COVID-19, Migraine, Nasopharyngitis, Oropharyngeal blistering, Paranasal sinus discomfort
Clinical narrative: I started getting migraines the day after the vaccine and lasted for 4 weeks. They finally went away after going to massage therapist and chiropractor 3 times. In January I went to urgent care I felt like I had a cold and they found white spots in my throat. I was given antibiotics. A few days later I took a Covid test and came back positive. I had sinus pressure and congestion and about a week and a half later it went away.
Age: 40.0
Sex: F
Vaccine: COVID19-2, FLUA4
Symptoms: SARS-CoV-2 test positive, Sinus congestion
Clinical narrative: I started getting migraines the day after the vaccine and lasted for 4 weeks. They finally went away after going to massage therapist and chiropractor 3 times. In January I went to urgent care I felt like I had a cold and they found white spots in my throat. I was given antibiotics. A few days later I took a Covid test and came back positive. I had sinus pressure and congestion and about a week and a half later it went away.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure increased, Blood test normal, Chest discomfort, Dizziness, Dyspnoea
Clinical narrative: The adverse event was tightening  of chest, dizziness, shortness of breath, increased blood pressure, hot flashes, and a slight headache. I don't know if the vaccine is the cause or not but I cannot rule it out.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Electrocardiogram normal, Headache, High density lipoprotein decreased, Hot flush, Low density lipoprotein normal
Clinical narrative: The adverse event was tightening  of chest, dizziness, shortness of breath, increased blood pressure, hot flashes, and a slight headache. I don't know if the vaccine is the cause or not but I cannot rule it out.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Urine analysis normal
Clinical narrative: The adverse event was tightening  of chest, dizziness, shortness of breath, increased blood pressure, hot flashes, and a slight headache. I don't know if the vaccine is the cause or not but I cannot rule it out.
Age: 89.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: 01/03/23 presents to ED for "breathing problem". PMHx of "HTN, CAD, CHF, recent hip fracture sp repair"
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site swelling
Clinical narrative: Within two days after receiving the vaccine, I developed a raised pink spot at the injection spot which lasted about a week. I used cortisone cream and BENADRYL spray it helped to relieve my symptoms. I did not see a doctor and self-treated.
Age: 83.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, Vaccine breakthrough infection
Clinical narrative: Breakthrough COVID
Age: 43.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Chest pain, SARS-CoV-2 test positive
Clinical narrative: 01/03/23 presents to ED for "chest pain, corona virus concern". PMHx of "HTN, SVT, HLD"
Age: 60.0
Sex: U
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: Community outreach completed at Nursing Home. Consents signed by Nursing Home administrators/guardians for patient to receive vaccine. Health Center staff thought nursing home had record of primary dose series of covid vaccine that was not entered to show me vax. Bivalent dose given as error that now, per CDC recommendations will serve as the "1st dose" and vaccine series will be completed correctly
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: 01/04/23 presents to the ED for "shortness of breath". PMHx of "COPD on 2 L, CAD, hyperlipidemia"
Age: 59.0
Sex: U
Vaccine: COVID19-2
Symptoms: Incorrect product formulation administered
Clinical narrative: Community outreach completed at local Nursing Home. Consents signed by Nursing Home administrators/guardians for patient to receive vaccine. Health Center staff thought nursing home had record of primary dose series of covid vaccine that was not entered to show me vax. Bivalent dose given as error that now, per CDC recommendations will serve as the "1st dose" and vaccine series will be completed correctly.
Age: 4.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect product formulation administered, No adverse event
Clinical narrative: No adverse effects, bivalent given instead of monovalent for second dose.
Age: 14.0
Sex: M
Vaccine: MMRV, VARCEL, MMRV, VARCEL
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: No adverse event at this time. Reporting incorrect dosing.
Age: 14.0
Sex: M
Vaccine: MMRV, VARCEL, MMRV, VARCEL
Symptoms: Product administered to patient of inappropriate age, Product administration error
Clinical narrative: No adverse event at this time. Reporting incorrect dosing.
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: 01/04/23 presents to ED for "shortness of breath". PMHx of "prostate cancer, UTI, GERD, Interstitial lung disease, COPD"
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: 01/04/23 presents to ED for "shortness of breath". PMHx of "Sjogren's disease"
Age: 1.75
Sex: F
Vaccine: HEP
Symptoms: Wrong product administered
Clinical narrative: Patient was to receive Hepatitis A vaccine at patient's wellness visit; however, patient received Hepatitis B instead.  Hepatitis A vaccine will be administered at next wellness visit.
Age: 79.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: Burning sensation, Laboratory test normal, Nerve conduction studies, Paraesthesia, Quantitative sudomotor axon reflex test
Clinical narrative: After receiving he October vaccine I developed tingling and burning in both feet.  Have been diagnosed with small fiber neuropathy.
Age: 79.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: Small fibre neuropathy
Clinical narrative: After receiving he October vaccine I developed tingling and burning in both feet.  Have been diagnosed with small fiber neuropathy.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: Back pain, COVID-19, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: 01/04/23 presents to ED for "low back pain" "shortness of breath". PMHx of "hyperlipidemia, depression, and chronic back pain"
Age: 1.17
Sex: F
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: wrong vaccine given, no adverse reactions
Age: 76.0
Sex: F
Vaccine: COVID19-2
Symptoms: Arthralgia, Joint swelling, Pain in extremity, X-ray
Clinical narrative: Patient reports acute onset right food and ankle pain which started within 24 hours of COVID-19 bivalent booster.  Patient reports 9/10 pain with significant ankle swelling.
Sex: M
Vaccine: HEP
Symptoms: Incorrect dose administered
Clinical narrative: Patient was given a Adult dose of Hepatitis B vaccine instead of ped/adol
Age: 0.17
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV1
Symptoms: Irritability, Pain, Screaming, Ultrasound abdomen
Clinical narrative: Intermittent episodes of screaming in pain and increase in fussiness with feeds
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Angiogram abnormal, Arteriosclerosis, Asthenia, Atrial fibrillation, Blood lactic acid
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR.  Provider d/c note:  "87 YO-year-old male with h/o Afib on Eliquis, CAD, CVA, DVT, HTN, hyperlipidemia, T2DM, Depression who presented due to complaints of altered mental status and weakness.  The patient was initially found at home after failing to appear to telehealth visit by family.  On admission patient reported of sore throat started past Monday with dry cough and indicated he had a fever overnight however was unmeasured.  In the emergency department patient's vitals:  Febrile 103.1F, tachycardic 105, tachypneic 24, stabbing 97% on room air.  Lab work significant for WBC 2.7, HGB 13.9, procalcitonin 0.11, TSH 0.36, BNP 443, lactate 1.7.  COVID testing returned positive results for COVID-19, chest x-ray showed mild interstitial edema.  CT head showed no acute intracranial abnormalities, chronic microvascular ischemic changes, mild cerebral and cerebellar atrophy, partial opacification of mastoid air cells.  CTA showed no large vessel occlusions, hypoplastic right vertebral artery, 3.4 cm thyroid mass, atherosclerotic plaque.  Patient was given Ofirmev and admitted to the inpatient hospital team for further evaluation and management of COVID-19.  For his COVID-19 patient is not a candidate for dexamethasone as he was not hypoxic, fever control was achieved with scheduled Tylenol and ofirmev.  albuterol, Mucinex and aggressive pulmonary toileting was attempted however patient continued to have difficulty expelling oral secretions further acquiring p.r.n. suctioning.  During the course of patient's stay patient entered into AFib with RVR, rate control initially attempted with labetalol IV, digoxin, diltiazem with IV GTT (initially achieved rate control for a few moments) patient re-entered AFib with RVR additional doses of Digoxin+ diltiazem were able to convert patient once again however patient continued to return into RVR ultimately requiring amiodarone an additional dose of IV labetalol. (Cardiology curbside recommended attempting additional dig or labetalol)  Rapid response was called on patient we was noted to have worsening altered mental status, during rapid response patient was noted to have seizure-like activity biting his tongue  was given Ativan and Keppra.  Patient continued to become tachypneic using accessory respiratory muscles.  Concern for CNS infection was present however patient did not have any meningeal signs such as nuchal rigidity though as a precaution patient was started on IV vancomycin, ampicillin, ceftriaxone with orders for EEG, CT head, MRI in place.  Patient was do not resuscitate DNI and patient's family did not want to change his status as such.  Overnight patient's condition continued to worsen and patient's family decided to resort to comfort measures.  Shortly after conversion to comfort measures patient had passed, time of death called at 4:33 a.m., family at bedside."
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood thyroid stimulating hormone decreased, Brain natriuretic peptide increased, COVID-19, Cardioversion, Cerebellar atrophy
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR.  Provider d/c note:  "87 YO-year-old male with h/o Afib on Eliquis, CAD, CVA, DVT, HTN, hyperlipidemia, T2DM, Depression who presented due to complaints of altered mental status and weakness.  The patient was initially found at home after failing to appear to telehealth visit by family.  On admission patient reported of sore throat started past Monday with dry cough and indicated he had a fever overnight however was unmeasured.  In the emergency department patient's vitals:  Febrile 103.1F, tachycardic 105, tachypneic 24, stabbing 97% on room air.  Lab work significant for WBC 2.7, HGB 13.9, procalcitonin 0.11, TSH 0.36, BNP 443, lactate 1.7.  COVID testing returned positive results for COVID-19, chest x-ray showed mild interstitial edema.  CT head showed no acute intracranial abnormalities, chronic microvascular ischemic changes, mild cerebral and cerebellar atrophy, partial opacification of mastoid air cells.  CTA showed no large vessel occlusions, hypoplastic right vertebral artery, 3.4 cm thyroid mass, atherosclerotic plaque.  Patient was given Ofirmev and admitted to the inpatient hospital team for further evaluation and management of COVID-19.  For his COVID-19 patient is not a candidate for dexamethasone as he was not hypoxic, fever control was achieved with scheduled Tylenol and ofirmev.  albuterol, Mucinex and aggressive pulmonary toileting was attempted however patient continued to have difficulty expelling oral secretions further acquiring p.r.n. suctioning.  During the course of patient's stay patient entered into AFib with RVR, rate control initially attempted with labetalol IV, digoxin, diltiazem with IV GTT (initially achieved rate control for a few moments) patient re-entered AFib with RVR additional doses of Digoxin+ diltiazem were able to convert patient once again however patient continued to return into RVR ultimately requiring amiodarone an additional dose of IV labetalol. (Cardiology curbside recommended attempting additional dig or labetalol)  Rapid response was called on patient we was noted to have worsening altered mental status, during rapid response patient was noted to have seizure-like activity biting his tongue  was given Ativan and Keppra.  Patient continued to become tachypneic using accessory respiratory muscles.  Concern for CNS infection was present however patient did not have any meningeal signs such as nuchal rigidity though as a precaution patient was started on IV vancomycin, ampicillin, ceftriaxone with orders for EEG, CT head, MRI in place.  Patient was do not resuscitate DNI and patient's family did not want to change his status as such.  Overnight patient's condition continued to worsen and patient's family decided to resort to comfort measures.  Shortly after conversion to comfort measures patient had passed, time of death called at 4:33 a.m., family at bedside."
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Cerebral atrophy, Cerebral ischaemia, Chest X-ray abnormal, Computerised tomogram head abnormal, Condition aggravated
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR.  Provider d/c note:  "87 YO-year-old male with h/o Afib on Eliquis, CAD, CVA, DVT, HTN, hyperlipidemia, T2DM, Depression who presented due to complaints of altered mental status and weakness.  The patient was initially found at home after failing to appear to telehealth visit by family.  On admission patient reported of sore throat started past Monday with dry cough and indicated he had a fever overnight however was unmeasured.  In the emergency department patient's vitals:  Febrile 103.1F, tachycardic 105, tachypneic 24, stabbing 97% on room air.  Lab work significant for WBC 2.7, HGB 13.9, procalcitonin 0.11, TSH 0.36, BNP 443, lactate 1.7.  COVID testing returned positive results for COVID-19, chest x-ray showed mild interstitial edema.  CT head showed no acute intracranial abnormalities, chronic microvascular ischemic changes, mild cerebral and cerebellar atrophy, partial opacification of mastoid air cells.  CTA showed no large vessel occlusions, hypoplastic right vertebral artery, 3.4 cm thyroid mass, atherosclerotic plaque.  Patient was given Ofirmev and admitted to the inpatient hospital team for further evaluation and management of COVID-19.  For his COVID-19 patient is not a candidate for dexamethasone as he was not hypoxic, fever control was achieved with scheduled Tylenol and ofirmev.  albuterol, Mucinex and aggressive pulmonary toileting was attempted however patient continued to have difficulty expelling oral secretions further acquiring p.r.n. suctioning.  During the course of patient's stay patient entered into AFib with RVR, rate control initially attempted with labetalol IV, digoxin, diltiazem with IV GTT (initially achieved rate control for a few moments) patient re-entered AFib with RVR additional doses of Digoxin+ diltiazem were able to convert patient once again however patient continued to return into RVR ultimately requiring amiodarone an additional dose of IV labetalol. (Cardiology curbside recommended attempting additional dig or labetalol)  Rapid response was called on patient we was noted to have worsening altered mental status, during rapid response patient was noted to have seizure-like activity biting his tongue  was given Ativan and Keppra.  Patient continued to become tachypneic using accessory respiratory muscles.  Concern for CNS infection was present however patient did not have any meningeal signs such as nuchal rigidity though as a precaution patient was started on IV vancomycin, ampicillin, ceftriaxone with orders for EEG, CT head, MRI in place.  Patient was do not resuscitate DNI and patient's family did not want to change his status as such.  Overnight patient's condition continued to worsen and patient's family decided to resort to comfort measures.  Shortly after conversion to comfort measures patient had passed, time of death called at 4:33 a.m., family at bedside."
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Cough, Death, General physical health deterioration, Haemoglobin decreased, Mental status changes
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR.  Provider d/c note:  "87 YO-year-old male with h/o Afib on Eliquis, CAD, CVA, DVT, HTN, hyperlipidemia, T2DM, Depression who presented due to complaints of altered mental status and weakness.  The patient was initially found at home after failing to appear to telehealth visit by family.  On admission patient reported of sore throat started past Monday with dry cough and indicated he had a fever overnight however was unmeasured.  In the emergency department patient's vitals:  Febrile 103.1F, tachycardic 105, tachypneic 24, stabbing 97% on room air.  Lab work significant for WBC 2.7, HGB 13.9, procalcitonin 0.11, TSH 0.36, BNP 443, lactate 1.7.  COVID testing returned positive results for COVID-19, chest x-ray showed mild interstitial edema.  CT head showed no acute intracranial abnormalities, chronic microvascular ischemic changes, mild cerebral and cerebellar atrophy, partial opacification of mastoid air cells.  CTA showed no large vessel occlusions, hypoplastic right vertebral artery, 3.4 cm thyroid mass, atherosclerotic plaque.  Patient was given Ofirmev and admitted to the inpatient hospital team for further evaluation and management of COVID-19.  For his COVID-19 patient is not a candidate for dexamethasone as he was not hypoxic, fever control was achieved with scheduled Tylenol and ofirmev.  albuterol, Mucinex and aggressive pulmonary toileting was attempted however patient continued to have difficulty expelling oral secretions further acquiring p.r.n. suctioning.  During the course of patient's stay patient entered into AFib with RVR, rate control initially attempted with labetalol IV, digoxin, diltiazem with IV GTT (initially achieved rate control for a few moments) patient re-entered AFib with RVR additional doses of Digoxin+ diltiazem were able to convert patient once again however patient continued to return into RVR ultimately requiring amiodarone an additional dose of IV labetalol. (Cardiology curbside recommended attempting additional dig or labetalol)  Rapid response was called on patient we was noted to have worsening altered mental status, during rapid response patient was noted to have seizure-like activity biting his tongue  was given Ativan and Keppra.  Patient continued to become tachypneic using accessory respiratory muscles.  Concern for CNS infection was present however patient did not have any meningeal signs such as nuchal rigidity though as a precaution patient was started on IV vancomycin, ampicillin, ceftriaxone with orders for EEG, CT head, MRI in place.  Patient was do not resuscitate DNI and patient's family did not want to change his status as such.  Overnight patient's condition continued to worsen and patient's family decided to resort to comfort measures.  Shortly after conversion to comfort measures patient had passed, time of death called at 4:33 a.m., family at bedside."
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Oropharyngeal pain, Procalcitonin, Pulmonary oedema, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR.  Provider d/c note:  "87 YO-year-old male with h/o Afib on Eliquis, CAD, CVA, DVT, HTN, hyperlipidemia, T2DM, Depression who presented due to complaints of altered mental status and weakness.  The patient was initially found at home after failing to appear to telehealth visit by family.  On admission patient reported of sore throat started past Monday with dry cough and indicated he had a fever overnight however was unmeasured.  In the emergency department patient's vitals:  Febrile 103.1F, tachycardic 105, tachypneic 24, stabbing 97% on room air.  Lab work significant for WBC 2.7, HGB 13.9, procalcitonin 0.11, TSH 0.36, BNP 443, lactate 1.7.  COVID testing returned positive results for COVID-19, chest x-ray showed mild interstitial edema.  CT head showed no acute intracranial abnormalities, chronic microvascular ischemic changes, mild cerebral and cerebellar atrophy, partial opacification of mastoid air cells.  CTA showed no large vessel occlusions, hypoplastic right vertebral artery, 3.4 cm thyroid mass, atherosclerotic plaque.  Patient was given Ofirmev and admitted to the inpatient hospital team for further evaluation and management of COVID-19.  For his COVID-19 patient is not a candidate for dexamethasone as he was not hypoxic, fever control was achieved with scheduled Tylenol and ofirmev.  albuterol, Mucinex and aggressive pulmonary toileting was attempted however patient continued to have difficulty expelling oral secretions further acquiring p.r.n. suctioning.  During the course of patient's stay patient entered into AFib with RVR, rate control initially attempted with labetalol IV, digoxin, diltiazem with IV GTT (initially achieved rate control for a few moments) patient re-entered AFib with RVR additional doses of Digoxin+ diltiazem were able to convert patient once again however patient continued to return into RVR ultimately requiring amiodarone an additional dose of IV labetalol. (Cardiology curbside recommended attempting additional dig or labetalol)  Rapid response was called on patient we was noted to have worsening altered mental status, during rapid response patient was noted to have seizure-like activity biting his tongue  was given Ativan and Keppra.  Patient continued to become tachypneic using accessory respiratory muscles.  Concern for CNS infection was present however patient did not have any meningeal signs such as nuchal rigidity though as a precaution patient was started on IV vancomycin, ampicillin, ceftriaxone with orders for EEG, CT head, MRI in place.  Patient was do not resuscitate DNI and patient's family did not want to change his status as such.  Overnight patient's condition continued to worsen and patient's family decided to resort to comfort measures.  Shortly after conversion to comfort measures patient had passed, time of death called at 4:33 a.m., family at bedside."
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Seizure like phenomena, Sputum retention, Tachycardia, Tachypnoea, Thyroid mass
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR.  Provider d/c note:  "87 YO-year-old male with h/o Afib on Eliquis, CAD, CVA, DVT, HTN, hyperlipidemia, T2DM, Depression who presented due to complaints of altered mental status and weakness.  The patient was initially found at home after failing to appear to telehealth visit by family.  On admission patient reported of sore throat started past Monday with dry cough and indicated he had a fever overnight however was unmeasured.  In the emergency department patient's vitals:  Febrile 103.1F, tachycardic 105, tachypneic 24, stabbing 97% on room air.  Lab work significant for WBC 2.7, HGB 13.9, procalcitonin 0.11, TSH 0.36, BNP 443, lactate 1.7.  COVID testing returned positive results for COVID-19, chest x-ray showed mild interstitial edema.  CT head showed no acute intracranial abnormalities, chronic microvascular ischemic changes, mild cerebral and cerebellar atrophy, partial opacification of mastoid air cells.  CTA showed no large vessel occlusions, hypoplastic right vertebral artery, 3.4 cm thyroid mass, atherosclerotic plaque.  Patient was given Ofirmev and admitted to the inpatient hospital team for further evaluation and management of COVID-19.  For his COVID-19 patient is not a candidate for dexamethasone as he was not hypoxic, fever control was achieved with scheduled Tylenol and ofirmev.  albuterol, Mucinex and aggressive pulmonary toileting was attempted however patient continued to have difficulty expelling oral secretions further acquiring p.r.n. suctioning.  During the course of patient's stay patient entered into AFib with RVR, rate control initially attempted with labetalol IV, digoxin, diltiazem with IV GTT (initially achieved rate control for a few moments) patient re-entered AFib with RVR additional doses of Digoxin+ diltiazem were able to convert patient once again however patient continued to return into RVR ultimately requiring amiodarone an additional dose of IV labetalol. (Cardiology curbside recommended attempting additional dig or labetalol)  Rapid response was called on patient we was noted to have worsening altered mental status, during rapid response patient was noted to have seizure-like activity biting his tongue  was given Ativan and Keppra.  Patient continued to become tachypneic using accessory respiratory muscles.  Concern for CNS infection was present however patient did not have any meningeal signs such as nuchal rigidity though as a precaution patient was started on IV vancomycin, ampicillin, ceftriaxone with orders for EEG, CT head, MRI in place.  Patient was do not resuscitate DNI and patient's family did not want to change his status as such.  Overnight patient's condition continued to worsen and patient's family decided to resort to comfort measures.  Shortly after conversion to comfort measures patient had passed, time of death called at 4:33 a.m., family at bedside."
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tongue biting, Use of accessory respiratory muscles, Vertebral artery hypoplasia, White blood cell count decreased
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR.  Provider d/c note:  "87 YO-year-old male with h/o Afib on Eliquis, CAD, CVA, DVT, HTN, hyperlipidemia, T2DM, Depression who presented due to complaints of altered mental status and weakness.  The patient was initially found at home after failing to appear to telehealth visit by family.  On admission patient reported of sore throat started past Monday with dry cough and indicated he had a fever overnight however was unmeasured.  In the emergency department patient's vitals:  Febrile 103.1F, tachycardic 105, tachypneic 24, stabbing 97% on room air.  Lab work significant for WBC 2.7, HGB 13.9, procalcitonin 0.11, TSH 0.36, BNP 443, lactate 1.7.  COVID testing returned positive results for COVID-19, chest x-ray showed mild interstitial edema.  CT head showed no acute intracranial abnormalities, chronic microvascular ischemic changes, mild cerebral and cerebellar atrophy, partial opacification of mastoid air cells.  CTA showed no large vessel occlusions, hypoplastic right vertebral artery, 3.4 cm thyroid mass, atherosclerotic plaque.  Patient was given Ofirmev and admitted to the inpatient hospital team for further evaluation and management of COVID-19.  For his COVID-19 patient is not a candidate for dexamethasone as he was not hypoxic, fever control was achieved with scheduled Tylenol and ofirmev.  albuterol, Mucinex and aggressive pulmonary toileting was attempted however patient continued to have difficulty expelling oral secretions further acquiring p.r.n. suctioning.  During the course of patient's stay patient entered into AFib with RVR, rate control initially attempted with labetalol IV, digoxin, diltiazem with IV GTT (initially achieved rate control for a few moments) patient re-entered AFib with RVR additional doses of Digoxin+ diltiazem were able to convert patient once again however patient continued to return into RVR ultimately requiring amiodarone an additional dose of IV labetalol. (Cardiology curbside recommended attempting additional dig or labetalol)  Rapid response was called on patient we was noted to have worsening altered mental status, during rapid response patient was noted to have seizure-like activity biting his tongue  was given Ativan and Keppra.  Patient continued to become tachypneic using accessory respiratory muscles.  Concern for CNS infection was present however patient did not have any meningeal signs such as nuchal rigidity though as a precaution patient was started on IV vancomycin, ampicillin, ceftriaxone with orders for EEG, CT head, MRI in place.  Patient was do not resuscitate DNI and patient's family did not want to change his status as such.  Overnight patient's condition continued to worsen and patient's family decided to resort to comfort measures.  Shortly after conversion to comfort measures patient had passed, time of death called at 4:33 a.m., family at bedside."
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose increased, Pain in extremity, Type 1 diabetes mellitus
Clinical narrative: I had a little soreness in my left arm after receiving the vaccine. I noticed my blood sugar was running higher than normal in July 2022, so I contacted my doctor. I was diagnosed with type 1 instead of type 2 diabetes. I was informed that my pancreas was not producing insulin like it should.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Blood test, Laboratory test, Limb discomfort, Pain in extremity
Clinical narrative: When I would walk or go up and down stairs, my right leg started to feel like it was hyperextending. Mostly this happened on the stairs. I noticed it, but just kept going and figured I just hurt myself. In November 2021, I was walking up the stairs and it happened again and it really hurt. I went to the doctor in December 2021, and we set up a plan for me to go to physical therapy. I put it off for a little while and didn't go until spring 2022. After physical therapy, I started to feel better. I had started to lose weight and it seemed to help as well. Around July 2022, I started to experience the pain again to where I noticed it. I had also started going back to the gym and I feel that maybe it aggravated my knee and joints. I went back to the doctor around September 2022, where I received another referral for physical therapy. I finished physical therapy in January 2023, and as of now, I feel that it has helped. My last flare up with my knee was around mid January.